\
            
             &
            
        
    
            Contact us
        
This was 6 months ago
Locationİstanbul, Türkiye
An international matchmaking event will be held in Istanbul as an opportunity to find European and Turkish partners both from the research and industrial communities to apply to upcoming Horizon Europe calls.
The Brokerage will include opportunities to form new partnerships through four parallel workshops on the topics: 
A limited number of participants of countries affiliated to the Horizon Europe programme can apply for reimbursement for travel and accommodation expenses (!this is only possibly before 10 March 2025). A full description of the reimbursement procedure is available here: https://lnkd.in/dyWX2YgR
More information on the event, the agenda and registration on the event website. Registration is open until 7 April. 
                We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020). 
                Stay informed about what matters to you.
                By signing up, you can opt in for e-mail notifications and get access to
                a personalised dashboard that groups all news updates and event announcements in your domain(s).
            
Only for stakeholders located in Flanders
                        
                    The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.